PROFILO/IDENTIKIT DEL NON ADERENTE:

- femmina - > 65 anni - obesa

- licenza elementare o media - casalinga

Tale identikit mirano a fornire al farmacista il profilo di paziente al quale rivolgere particolari attenzioni come target del proprio intervento professionale, mettendo in atto tutte quelle strategie e attenzioni di presa in carico del paziente, quali migliori spiegazioni e ripetuti monitoraggi, al fine di incrementare l’aderenza terapeutica della categoria “non-aderenti”, in modo da ottimizzare sia gli outcomes clinici che l’impatto economico sul SSN.

BIBLIOGRAFIA

Adeyl O., Smith O., & Robles S.. Public policy and the challenge of chronic noncommunicable diseases. Washington D.C., World Bank, 2007

Aljboury T.M., Alkhawaldeh M.S., Abu-Rumman Ala’a eddeen K., Hasan T.A., Khattar H.M., Abu-Oliem A.S.. Impact of clinical pharmacist on cost of drug therapy in the ICU. Saudi Pharm J 2013; 21(4): 371-374.

Alam U., Asghar O., Azmi S, Malik R.A.. General aspects of diabetes mellitus. Handb Clin Neurol. 2014;126: 211-222

Allemann S.S., van Mil J.W.F., Botermann L., Berger K., Griese N., Hersberger K.E.. Pharmaceutical Care: the PCNE definition 2013. Int J Clin Pharm Jun 2014; 36(3):544-555.

Al Mazroui N.R., Kamal M.M., Ghabash N.M., Yacout T.A., Kole P.L., McElnay J.C.. Influence of pharmaceutical care on health outcomes in patients with type 2 diabetes mellitus. Br J Clin Pharmacol 2009; 67(5):547-557.

Antoine S.L, Pieper D., Mathes T., Eikermann M.. Improving the adherence oftype 2 diabetes mellitus patients with pharmacy care: a systematic review of randomized controlled trials. BMC Endocr Disord 2014; 14-53

Azhar S., Hassali M.A., Ibrahim M.I., Ahmad M., Masood I., Shafie A.A.. The role of pharmacists in developing countries: the current scenario in Pakistan. Hum Resour Health 2009; 7-54.

Barber N.. Pharmaceutical care and medicines management, is there a difference? Pharm World Sci 2001 Dec; 23(6):205-209.

Barquera S., Campos-Nonato I., Aguilar-Salinas C., Lopez-Ridaura R., Arredondo A., Rivera-Dommarco J.. Diabetes in Mexico: cost and management of diabetes and its complications and challenges for health policy. Global Health 2013, 9-30

Behmane D., Innus J.. Pharmaceutical policy and the effects of the economic crisis: Latvia. Eurohealth 2011; 4:69-79

Berenguer B., Lacasa C., de La Matta M.J., Martin-Calaro M.J.. Pharmaceutical care: Past, Present and Future. Curr Pharm Des 2004; 10(31): 3931-3946

Blair S.N.. Physical inactivity: The biggest public health problem of the 21st century. Br J Sports Med 2009; 43: 1-2

Bunting B.A., Cranor C.W.. The Asheville Project: long-term clinical, humanistic, and economic outcomes of a community-based medication therapy management program for asthma. J Am Pharm Assoc (2003) 2006 Mar-Apr; 46(2):133-147.

Bunting B.A., Smith B.H., Sutherland S.E.. The Asheville Project: clinical and economic outcomes of a community-based long-term medication therapy management program for hypertension and dyslipidemia. J Am Pharm Assoc (2003) 2008; 48(1):23-31

Bury M.. Chronic illness as biographical disruption. Sociol Health Illn. 1982;4(2)167-182

Caamaño F., Alvarez R., Khoury M.. The community pharmacists and their practice as health care providers. Gac Sanit. 2008; 22(4): 385

Cassel J.. The contribution of social environment to host resistance. Am J Epidemiol. 1976;104(2)107-123

Clifford R.M., Davis W.A., Batty K.T., Davis T.M.. Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care 2005; 28(4):771-776.

Clifford S., Garfield S., Eliasson L., Barber N.. Medication adherence and community pharmacy: a review of education, policy and research in England. Pharm Pract (Granada) 2010; 8(2):77-88.

Cobb S.. Social support as a moderator of life stress. Psychosom. Med. 1976(38) 300-314.

Cramer J.A., Okikawa J., Bellaire S., Clauson P.. Compliance with inhaled insulin treatment using the AERx (registered trademark) iDMS insulin diabetes management system. Diab Technol Ther 2004; 6(6):

800-807.

Crealey G.E., Sturgess I.K., McElnay J.C., Hughes C.M.. Pharmaceutical care programmes for the elderly: economic issues. Pharmacoeconomics 2003; 21(7):455-465.

Cranor C.W., Christensen D.B.. The Asheville Project: short-term outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc (Wash) 2003 Mar-Apr; 43(2):149-159.

Danaei G., Finucane M.M., Lu Y., Singh G.M., Cowan M.J., Paciorek C.J.. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet, 2011. 378(9785):31-40

de Graaf F.R., Schuijf J.D., Scholte A.J.. Usefulness of hypertriglyceridemic waist phenotype in type 2 diabetes mellitus to predict the presence of coronary artery disease as assessed by computed tomographic coronary angiography. Am J Cardiol 2010; 106: 1747-1753 Donato R., March G., Moss J., Gilbert A.. Cost implications of the delivery of pharmaceutical care services through Australian community pharmacies. Int J Pharm Pract 2001; 9(1):23-30.

Elliot R.. Non-adherence to medicines: not solved but solvable. J Health Serv Res Policy 2009; 14(1):58-61.

Ekelund U., Brage S., Franks P.W., Physical activity energy expenditure predicts progression toward the metabolic syndrome independently of aerobic fitness in middle-aged healthy Caucasians: The Medical Research Council Ely Study. Diabetes Care 2005; 28: 1195-1200

Farris K.B., Fernandez-Llimos F., Benrimoj S.I.. Pharmaceutical care in community pharmacies: practice and research from around the world. Ann Pharmacother 2005; 39(9):1539-1541.

Garuoliene K., Alonderis T., Marinkevicius M.. Eurohealth: Pharmaceutical policy and the effects of the economic crisis: Lithuania. Eurohealth 2011;17(1):1-4.

Geneau R, Stuckler D, Stachenko S, McKee M, Ebrahim S, Basu S, et al. Raising the priority of preventing chronic diseases, a political process. Lancet, 2010;376(13)1689-1698

Gerhardt U.. Qualitative research on chronic illness: The issue and the story. Soc Sci Med 1990; 30(11): V-VI. 1149-1159

white book: respiratory health and disease in Europe. In: The economic burden of lung disease. European Respiratory Society, 2013, 16-27

Gomez-Huelgas R., Bernal‐Lopez M.R., Villalobos A.. Hypertriglyceridemic waist: An alternative to the metabolic syndrome? Results of the IMAP Study (multidisciplinary intervention in primary care). Int J Obes (Lond) 2011; 35: 292-299.

Guariguata L.. By the numbers: New estimates from the IDF diabetes Atlas update for 2012. Diabetes Res Clin Pract 2012; 98: 524-525

Gurwitz J.H., Rochon P.. Considerations in designing an ideal medication- use system: lessons from caring for the elderly. Am J Health Syst Pharm 2000; 57(6): 548-551.

Gwadry-Sridhar F.H., Manias E., Lal L., Salas M., Hughes D.A., Ratzki- Leewing A., Grubisic M.. Impact of interventions on medication adherence and blood pressure control in patients with essential hypertension: a systematic review by the ISPOR medication adherence and persistence special interest group. Value Health 2013; 16(5):863-871.

Haynes R.B., Ackloo E., Sahota N., McDonald H.P., Yao X.. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008; (2):CD000011

Haynes R.B., Yao X., Degani A., Kripalani S., Garg A., McDonald H.P.. Interventions to enhance medication adherence. Cochrane Database Syst Rev 2005; 4:CD000011.

Hepler C.D., Strand L.M.. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990; 47:533-543.

Hisashige A.. The Effectiveness and Efficiency of Disease Management Programs for Patients with Chronic Diseases. Global Journal of Health Science 2013 Nov 26; 5(2):27-48.

Ho P.M., Rumsfeld J.S., Masoudi F.A., McClure D.L., Plomondon M.E., Steiner J.F., Magid D.J.. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006; 166(17):1836-1841.

Homedes N., Ugalde A.. Improving acces to pharmaceuticals in Brazil and Argentina. Health Policy Plan 2006; 21(2):123-131

Horne R., Barber N., Weinman J., Elliott R.A., Morgan M., Cribb A.. Concordance, adherence and compliance in medicine taking: a scoping exercise, London, NHS Nation Coordinat Cent Serv Deliv Organiz, 2006. Hussain A., Ibrahim M.I.. Medication counselling and dispensing practices at community pharmacies: a comparative cross sectional study from Pakistan. Int J Clin Pharm 2011; 33(5):859-867.a

Hussain A, Ibrahim MI.. Qualification, knowledge and experience of dispensers working at community pharmacies in Pakistan. Pharm Pract 2011; 9(2):93-100.b

Jameson J., VanNoord G., Vanderwoud K.. The impact of a pharmacotherapy consultation n the cost and outcome of medical therapy. J Fam Pract. Nov 1995; 41(5):469-472.

Jiménez-Corona A., Aguilar-Salinas C.A., Rojas-Martínez R., Hernández- Ávila M.. Diabetes mellitus tipo 2 y frecuencia de acciones para su prevención y control. Salud Publica Mex 2013;55 137-143

Johnson J.A., Bootman J.L.. Drug-related morbidity and mortality: a cost- ofillness model. Arch Int Med. 1995; 155(18):1949-1956.

Kafeel H., Rukh R., Naveed S.. Evalutation of patient counseling in different hospital of Karachi, Pakistan; a neglected domani of Pharmacy. J Pharm Internat Res 2014; 5(3):203-206.

Krska J., Manfrin A.. Pharmacist and GP views on a medicine use review pilot project conducted in Italy [abstract]. Research in Social and Administrative Pharmacy (2004) 2014 Sep-Oct; 10(5):38

Kesaniemi Y.K., Danforth E.J., Jensen M.D.. Dose‐response issues concerning physical activity and health: An evidence‐based symposium. Med Sci Sports Exerc 2001; 33: 351-358

Kinget R.. Put community pharmacy on a brand new track. Int Pharm J 2000; 14:4-7

Manfrin A., Caparrotta L., Krska J.. Evaluation of a pilot study involving MUR provision in Italy, using web-based data capture [abstract]. Int J Pharma Practice 2013; 21 Suppl 2:113-114.a

Manfrin A., Caparrotta L., Krska J.. Medicine Use Review pilot project in Italy. Full report sent to FOFI (Italian Pharmacists’ Federation). 2013.b

Manfrin A., Krska J.. Evaluation of feedback on medicines use reviews provided in Italy from patients with asthma [abstract]. Research in Social and Administrative Pharmacy 2014

Manfrin A., Thomas T., Krska J.. Randomised evaluation of the Italian medicines use review provided by community pharmacists using asthma as a model (RE I-MUR). BMC Health Serv Res 2015 Apr 21; 15-171.a

Marquez-Contreras E., Martell-Claros N., Gil-GuillÈn V., de la Figuera- Von W.M., Casado-MartÌnez J.J., Martin-de Pablos J.L., Figueras M., Galera J., Serra A.. Compliance group of the spanish society of Hypertention (SEE). Efficacy of a home blood pressure monitoring programme on therapeutic compliance in hypertension: the EAPACUM- HTA study. J Hypertens. 2006; 24(1):169-175.

Martín-Calero M.J., Machuca M., Murillo M.D., Cansino J., Gastelurrutia, Faus M.J.. Structural Process and Implementation Programs of Pharmaceutical Care in Different Countries. Curr Pharm Des 2004; 10(31):3969-3985.

Mathers C.D., Loncar D.. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med, 2006;3(11): 442

Morisky D.E., Green L.W., Levine D.M.. Concurrent and predictive validity of a self- reported measure of medication adherence. Med Care 1986; 24(1):67-74.

Morisky D.E., Levine D.M., Green L.W., Shapiro S., Russell R.P., Smith C.R.. Five-year blood pressure control and mortality following health education for hypertensive patients. Am J Public Health 1983; 73(2):153- 162.

Morrish N.J., Wang S.L., Stevens L.K., Fuller J.H., Keen H.. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetolog 2001.44: 14-21

O'Neil A., Williams E.D., Browne J.L., Horne R., Pouwer F., Speight J.. General aspects of diabetes mellitus.

Handb Clin Neurol. 2014;126: 211-222.

Pan American Health Organization (PAHO). Innovative Care for Chronic Conditions: Organizing and Delivering High Quality Care for Chronic Non-communicable Diseases in the Americas. Washington DC, USA: PAHO, 2013

Pharmaceutical Services Negotiating Committee (PSNC 2013). Medicines use reviews and prescription intervention service. 2016

Phumipamorn S., Pongwecharak J., Soorapan S., Pattharachayakul S.. Effects of the pharmacistís input on glycaemic control and cardiovascular risks in Muslim diabetes. Prim Care Diabetes 2008; 2(1):31-37.

Putnam R.D.. Bowling Alone: The Collapse & Revival of American Community. Simon & Schuster, New York, USA, 2000

Reach G.. Non-adherence to therapy in type 2 diabetes Presse Med. 2013;42(5): 886-892.

Ren Y., Luo X., Wang C.. Prevalence of hypertriglyceridemic waist and association with risk of type 2 diabetes mellitus: A meta‐analysis. Diabetes Metab Res Rev 2015.

Rissanen A., Fogelholm M.. Physical activity in the prevention and treatment of other morbid conditions and impairments associated with obesity: Current evidence and research issues. Med Sci Sports Exerc 1999; 31: 635-645

Roglic G., Unwin N., Bennett P.H., Mathers C., Tuomilehto J., Nag S.. The burden of mortality attributable to diabetes: Realistic estimates for the year 2000. Diabetes Care, 2005; 28(9): 2130-2135

Rüütel D., Pudersell K.. Pharmaceutical Policy and the effects of the economic crisis: Estonia. Eurohealth 2011; 17(1):5-8.

Santschi V., Chiolero A., Paradis G., Colosimo A.L., Burnand B.. Pharmacist Interventions to Improve Cardiovascular Disease Risk Factors in Diabetes. Diabetes Care 2012; 35(12):2706-2717.

Sapag J.C., Kawachi I.. Capital social y promoción de la salud. Rev Saúde Pública2007;41(1):139-149

Sarwar N., Gao P., Seshasai S.R., Gobin R., Kaptoge S., Di Angelantonio E.,Ingelsson E., Lawlor D.A., Selvin E., Stampfer M., Stehouwer C.D., Lewington S., Pennells L., Thompson A., Sattar N., White I.R., Ray K.K., Danesh J.. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375(9733):2215- 2222.

Schroeder K., Fahey T., Ebrahim S.. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev 2004; (2):CD004804.

Schnohr P., O'Keefe J.H., Marott J.L.. Dose of jogging and long‐term mortality: The copenhagen city heart study. J Am Coll Cardiol 2015; 65: 411-419

Seuring T., Archangelidi O., Suhrcke M.. The economic costs of type 2 diabetes: A global systematic review. Pharmacoeconomics 2015; 33: 1-21 Smith D.L.. The effect of patient non-compliance on health care costs. Med Interface 1993; 6(4):74-76,78,84

Spinewine A., Fialova D., Byrne S.. The role of the pharmacist in optimizing pharmacotherapy in older people. Drugs Aging 2012; 29(6):495-510.

Sriram S., Chack L.E., Ramasamy R., Ghasemi A., Ravi T.K., Sabzghabaee A.M.. Impact of pharmaceutical care on quality of life in patients with type 2 diabetes mellitus. J Res Med Sci 2011:412-418.

Stoner K.C., Ching M., Murray M.A.. Impact of a pharmaceutical care model on the management of congestive heart failure patients in a geriatric medicine teaching clinic. ASHP Annual Meeting 1998; 55

Strand L.M., Cipolle R.J., Morley P.C.. Pharmaceutical Care: An Introduction, Michigan, Upjohn Co, 1992, PP 14-29.

The Pharmaceutical care of the Elderly in Europe Research (PEER) Group. Improving the well-being of elderly patients via community pharmacy- based provision of pharmaceutical care: a multicentre study in seven European countries. Drugs Aging 2001; 18(1):63-77

Toklu H.Z., Akici A., Oktay S., Cali S., Sezen S.F., Keyer-Uysal M.. The pharmacy practice of community pharmacists in Turkey. Marmara Pharm J 2010; 14:53-60.

Toklu H.Z., Hussain A.. The changing face of pharmacy practice and the need for a new model of pharmacy education. J Young Pharm 2013 ; 5(2):38-40.

Van der Stuyft P., De Vos P., Hildebrand K.. USA and shortage of food and medicine in Cuba. Lancet 1997; 349(9048):363.

van Mil J.W.F., Fernandez-Llimos F.. What is ‘pharmaceutical care’ in 2013? Int J Clin Pharm 2013.

van Mill J.W.F., Schulz M., Tromp T.F.J.. Pharmaceutical care, European developmets in concepts, implementation, teaching, and research: a review. Pharm World Science December 2004; 26(6):303-311.

Vermeire E.I.J.J., Wens J., Van Royen P., Biot Y., Hearnshaw H., Lindenmeyer A.. Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; (2):CD003638.

Vervloet M., Linn A.J., van Weert J.C., de Bakker D.H., Bouvy M.L., van Dijk L.. The effectiveness of interventions using electronic reminders to improve adherence to chronic medication: a systematic review of the literature. J Am Med Inform Assoc. 2012; 19(5):696-704.

Vyncke V., Bart C., Stevens V., Costongs C., Barbareschi G., Hrafn S.. Does neighbourhood social capital aid in leveling the social gradient in the health and well-being of children and adolescents? A literature review. BMC Public Health 2013, 13-65

Wiffen P.. Evidence-based Pharmacy, Abingdon, Radcliffe Medical Press Ltd, 2001

Wilkinson R., Marmot M.. Social Determinants of Health The Solid Facts. World Health Organization, NLM Classification: WA30; Geneva, Switzerland, 2003.

World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications Part 1: Diagnosis and classification of diabetes mellitus. WHO. (WHO/NCD/NCS/99.2) Geneva, Switzerland, 1999.

World Health Organization. Adherence to Long-Term Therapies Evidence foraction, 2003.

World Health Organization. Report on the global status of non communicable diseases. WHO/NMH/CHP/11.1. Geneva, Switzerland, 2011.

Xu W.. Introduction to sports biochemistry. Higher Education Press, Beijing, 2005.

Ren Y., Zhang M., Zhao J., Wang C., Luo X., Zhang J., Zhu T., Li X., Yin L., Pang C., Feng T., Wang B., Zhang L. , Li L., Yang X., Zhang H., Hu D.. Associations between economic hardship and markers of self- management in adults with type 2 diabetes: results from Diabetes MILES - Australia Aust N Z J Public Health. 2014; 38(5):466-72.

Yordanova S., Petkova V.. Pharmaceutical care in some european countries, Australia, Canada and USA. World Journal of Pharmacy And Pharmaceutical Sciences 2013; 2(5):2291-2308.